Global Cushing’s Disease Treatment Market

Cushing’s Disease Treatment Comprehensive Study by Drug (Ketoconazole, Mitotane, Aminoglutethimide, Metyrapone, Mifepristone, Etomidate, Pasireotide), Cushing’s Syndrome (Iatrogenic Cushing’s Syndrome, Endogenous Cushing’s Syndrome), End User (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Clinics, E-Commerce/Online Pharmacies) Players and Region - Global Market Outlook to 2026

Cushing’s Disease Treatment Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Cushing’s Disease Treatment Market Overview:
Cushing's disease is caused by a tumor in the pituitary gland, which causes excessive release of the hormone adrenocorticotrophic (ACTH), which causes cortisol levels in the body to rise. Cortisol is a steroid hormone produced by the adrenal glands that aids in the body's recovery from injury or infection. Cortisol raises blood sugar levels and may also cause dizziness. Cushing’s disease treatment market revenue is expected to grow over the forecast period due to increasing investment in R&D and an increasing number of new product launches.

Growth Drivers
  • Increasing Awareness regarding Cushing Syndrome Aids
  • Rising in Geriatric Population

Market Trends
  • Increasing Number of Pipeline Drugs

Roadblocks
  • Side Effects of the Drug

Opportunities
  • Growing Healthcare Expenditure
  • Growing Interest of Pharmaceutical Companies to Develop Cushing Disease Drugs

Challenges
  • Lack of Awareness among the Consumer


Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Corcept Therapeutics (United States), HRA Pharma (France), Strongbridge Biopharma plc (United States) and Novartis AG (Switzerland). Analyst at AMA Research see Global Players to retain maximum share of Global Cushing’s Disease Treatment market by 2026. Considering Market by Drug, the sub-segment i.e. Ketoconazole will boost the Cushing’s Disease Treatment market. Considering Market by Cushing’s Syndrome, the sub-segment i.e. Iatrogenic Cushing’s Syndrome will boost the Cushing’s Disease Treatment market. Considering Market by End User, the sub-segment i.e. Hospital Pharmacies will boost the Cushing’s Disease Treatment market.

In Mar 2020, The U.S. Food and Drug Administration approved Isturisa (osilodrostat) oral tablets for adults with Cushing’s disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease. Cushing’s disease is a rare disease in which the adrenal glands make too much of the cortisol hormone. Isturisa is the first FDA-approved drug to directly address this cortisol overproduction by blocking the enzyme known as 11-beta-hydroxylase and preventing cortisol synthesis.

What Can be Explored with the Cushing’s Disease Treatment Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Cushing’s Disease Treatment Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Cushing’s Disease Treatment
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Cushing’s Disease Treatment market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Cushing’s Disease Treatment market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Cushing’s Disease Treatment Provider, Government Regulatory and Research Organizations and End-Use Industry.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Drug
  • Ketoconazole
  • Mitotane
  • Aminoglutethimide
  • Metyrapone
  • Mifepristone
  • Etomidate
  • Pasireotide

By Cushing’s Syndrome
  • Iatrogenic Cushing’s Syndrome
  • Endogenous Cushing’s Syndrome

By End User
  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Clinics
  • E-Commerce/Online Pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Awareness regarding Cushing Syndrome Aids
      • 3.2.2. Rising in Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness among the Consumer
    • 3.4. Market Trends
      • 3.4.1. Increasing Number of Pipeline Drugs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cushing’s Disease Treatment, by Drug, Cushing’s Syndrome, End User and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Cushing’s Disease Treatment (Value)
      • 5.2.1. Global Cushing’s Disease Treatment by: Drug (Value)
        • 5.2.1.1. Ketoconazole
        • 5.2.1.2. Mitotane
        • 5.2.1.3. Aminoglutethimide
        • 5.2.1.4. Metyrapone
        • 5.2.1.5. Mifepristone
        • 5.2.1.6. Etomidate
        • 5.2.1.7. Pasireotide
      • 5.2.2. Global Cushing’s Disease Treatment by: Cushing’s Syndrome (Value)
        • 5.2.2.1. Iatrogenic Cushing’s Syndrome
        • 5.2.2.2. Endogenous Cushing’s Syndrome
      • 5.2.3. Global Cushing’s Disease Treatment by: End User (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Drug Stores
        • 5.2.3.4. Clinics
        • 5.2.3.5. E-Commerce/Online Pharmacies
      • 5.2.4. Global Cushing’s Disease Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Cushing’s Disease Treatment (Price)
  • 6. Cushing’s Disease Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Corcept Therapeutics (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. HRA Pharma (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Strongbridge Biopharma plc (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
  • 7. Global Cushing’s Disease Treatment Sale, by Drug, Cushing’s Syndrome, End User and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Cushing’s Disease Treatment (Value)
      • 7.2.1. Global Cushing’s Disease Treatment by: Drug (Value)
        • 7.2.1.1. Ketoconazole
        • 7.2.1.2. Mitotane
        • 7.2.1.3. Aminoglutethimide
        • 7.2.1.4. Metyrapone
        • 7.2.1.5. Mifepristone
        • 7.2.1.6. Etomidate
        • 7.2.1.7. Pasireotide
      • 7.2.2. Global Cushing’s Disease Treatment by: Cushing’s Syndrome (Value)
        • 7.2.2.1. Iatrogenic Cushing’s Syndrome
        • 7.2.2.2. Endogenous Cushing’s Syndrome
      • 7.2.3. Global Cushing’s Disease Treatment by: End User (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Drug Stores
        • 7.2.3.4. Clinics
        • 7.2.3.5. E-Commerce/Online Pharmacies
      • 7.2.4. Global Cushing’s Disease Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Cushing’s Disease Treatment (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cushing’s Disease Treatment: by Drug(USD Million)
  • Table 2. Cushing’s Disease Treatment Ketoconazole , by Region USD Million (2015-2020)
  • Table 3. Cushing’s Disease Treatment Mitotane , by Region USD Million (2015-2020)
  • Table 4. Cushing’s Disease Treatment Aminoglutethimide , by Region USD Million (2015-2020)
  • Table 5. Cushing’s Disease Treatment Metyrapone , by Region USD Million (2015-2020)
  • Table 6. Cushing’s Disease Treatment Mifepristone , by Region USD Million (2015-2020)
  • Table 7. Cushing’s Disease Treatment Etomidate , by Region USD Million (2015-2020)
  • Table 8. Cushing’s Disease Treatment Pasireotide , by Region USD Million (2015-2020)
  • Table 9. Cushing’s Disease Treatment: by Cushing’s Syndrome(USD Million)
  • Table 10. Cushing’s Disease Treatment Iatrogenic Cushing’s Syndrome , by Region USD Million (2015-2020)
  • Table 11. Cushing’s Disease Treatment Endogenous Cushing’s Syndrome , by Region USD Million (2015-2020)
  • Table 12. Cushing’s Disease Treatment: by End User(USD Million)
  • Table 13. Cushing’s Disease Treatment Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 14. Cushing’s Disease Treatment Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 15. Cushing’s Disease Treatment Drug Stores , by Region USD Million (2015-2020)
  • Table 16. Cushing’s Disease Treatment Clinics , by Region USD Million (2015-2020)
  • Table 17. Cushing’s Disease Treatment E-Commerce/Online Pharmacies , by Region USD Million (2015-2020)
  • Table 18. South America Cushing’s Disease Treatment, by Country USD Million (2015-2020)
  • Table 19. South America Cushing’s Disease Treatment, by Drug USD Million (2015-2020)
  • Table 20. South America Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2015-2020)
  • Table 21. South America Cushing’s Disease Treatment, by End User USD Million (2015-2020)
  • Table 22. Brazil Cushing’s Disease Treatment, by Drug USD Million (2015-2020)
  • Table 23. Brazil Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2015-2020)
  • Table 24. Brazil Cushing’s Disease Treatment, by End User USD Million (2015-2020)
  • Table 25. Argentina Cushing’s Disease Treatment, by Drug USD Million (2015-2020)
  • Table 26. Argentina Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2015-2020)
  • Table 27. Argentina Cushing’s Disease Treatment, by End User USD Million (2015-2020)
  • Table 28. Rest of South America Cushing’s Disease Treatment, by Drug USD Million (2015-2020)
  • Table 29. Rest of South America Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2015-2020)
  • Table 30. Rest of South America Cushing’s Disease Treatment, by End User USD Million (2015-2020)
  • Table 31. Asia Pacific Cushing’s Disease Treatment, by Country USD Million (2015-2020)
  • Table 32. Asia Pacific Cushing’s Disease Treatment, by Drug USD Million (2015-2020)
  • Table 33. Asia Pacific Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2015-2020)
  • Table 34. Asia Pacific Cushing’s Disease Treatment, by End User USD Million (2015-2020)
  • Table 35. China Cushing’s Disease Treatment, by Drug USD Million (2015-2020)
  • Table 36. China Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2015-2020)
  • Table 37. China Cushing’s Disease Treatment, by End User USD Million (2015-2020)
  • Table 38. Japan Cushing’s Disease Treatment, by Drug USD Million (2015-2020)
  • Table 39. Japan Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2015-2020)
  • Table 40. Japan Cushing’s Disease Treatment, by End User USD Million (2015-2020)
  • Table 41. India Cushing’s Disease Treatment, by Drug USD Million (2015-2020)
  • Table 42. India Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2015-2020)
  • Table 43. India Cushing’s Disease Treatment, by End User USD Million (2015-2020)
  • Table 44. South Korea Cushing’s Disease Treatment, by Drug USD Million (2015-2020)
  • Table 45. South Korea Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2015-2020)
  • Table 46. South Korea Cushing’s Disease Treatment, by End User USD Million (2015-2020)
  • Table 47. Taiwan Cushing’s Disease Treatment, by Drug USD Million (2015-2020)
  • Table 48. Taiwan Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2015-2020)
  • Table 49. Taiwan Cushing’s Disease Treatment, by End User USD Million (2015-2020)
  • Table 50. Australia Cushing’s Disease Treatment, by Drug USD Million (2015-2020)
  • Table 51. Australia Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2015-2020)
  • Table 52. Australia Cushing’s Disease Treatment, by End User USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Cushing’s Disease Treatment, by Drug USD Million (2015-2020)
  • Table 54. Rest of Asia-Pacific Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2015-2020)
  • Table 55. Rest of Asia-Pacific Cushing’s Disease Treatment, by End User USD Million (2015-2020)
  • Table 56. Europe Cushing’s Disease Treatment, by Country USD Million (2015-2020)
  • Table 57. Europe Cushing’s Disease Treatment, by Drug USD Million (2015-2020)
  • Table 58. Europe Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2015-2020)
  • Table 59. Europe Cushing’s Disease Treatment, by End User USD Million (2015-2020)
  • Table 60. Germany Cushing’s Disease Treatment, by Drug USD Million (2015-2020)
  • Table 61. Germany Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2015-2020)
  • Table 62. Germany Cushing’s Disease Treatment, by End User USD Million (2015-2020)
  • Table 63. France Cushing’s Disease Treatment, by Drug USD Million (2015-2020)
  • Table 64. France Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2015-2020)
  • Table 65. France Cushing’s Disease Treatment, by End User USD Million (2015-2020)
  • Table 66. Italy Cushing’s Disease Treatment, by Drug USD Million (2015-2020)
  • Table 67. Italy Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2015-2020)
  • Table 68. Italy Cushing’s Disease Treatment, by End User USD Million (2015-2020)
  • Table 69. United Kingdom Cushing’s Disease Treatment, by Drug USD Million (2015-2020)
  • Table 70. United Kingdom Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2015-2020)
  • Table 71. United Kingdom Cushing’s Disease Treatment, by End User USD Million (2015-2020)
  • Table 72. Netherlands Cushing’s Disease Treatment, by Drug USD Million (2015-2020)
  • Table 73. Netherlands Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2015-2020)
  • Table 74. Netherlands Cushing’s Disease Treatment, by End User USD Million (2015-2020)
  • Table 75. Rest of Europe Cushing’s Disease Treatment, by Drug USD Million (2015-2020)
  • Table 76. Rest of Europe Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2015-2020)
  • Table 77. Rest of Europe Cushing’s Disease Treatment, by End User USD Million (2015-2020)
  • Table 78. MEA Cushing’s Disease Treatment, by Country USD Million (2015-2020)
  • Table 79. MEA Cushing’s Disease Treatment, by Drug USD Million (2015-2020)
  • Table 80. MEA Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2015-2020)
  • Table 81. MEA Cushing’s Disease Treatment, by End User USD Million (2015-2020)
  • Table 82. Middle East Cushing’s Disease Treatment, by Drug USD Million (2015-2020)
  • Table 83. Middle East Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2015-2020)
  • Table 84. Middle East Cushing’s Disease Treatment, by End User USD Million (2015-2020)
  • Table 85. Africa Cushing’s Disease Treatment, by Drug USD Million (2015-2020)
  • Table 86. Africa Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2015-2020)
  • Table 87. Africa Cushing’s Disease Treatment, by End User USD Million (2015-2020)
  • Table 88. North America Cushing’s Disease Treatment, by Country USD Million (2015-2020)
  • Table 89. North America Cushing’s Disease Treatment, by Drug USD Million (2015-2020)
  • Table 90. North America Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2015-2020)
  • Table 91. North America Cushing’s Disease Treatment, by End User USD Million (2015-2020)
  • Table 92. United States Cushing’s Disease Treatment, by Drug USD Million (2015-2020)
  • Table 93. United States Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2015-2020)
  • Table 94. United States Cushing’s Disease Treatment, by End User USD Million (2015-2020)
  • Table 95. Canada Cushing’s Disease Treatment, by Drug USD Million (2015-2020)
  • Table 96. Canada Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2015-2020)
  • Table 97. Canada Cushing’s Disease Treatment, by End User USD Million (2015-2020)
  • Table 98. Mexico Cushing’s Disease Treatment, by Drug USD Million (2015-2020)
  • Table 99. Mexico Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2015-2020)
  • Table 100. Mexico Cushing’s Disease Treatment, by End User USD Million (2015-2020)
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Cushing’s Disease Treatment: by Drug(USD Million)
  • Table 106. Cushing’s Disease Treatment Ketoconazole , by Region USD Million (2021-2026)
  • Table 107. Cushing’s Disease Treatment Mitotane , by Region USD Million (2021-2026)
  • Table 108. Cushing’s Disease Treatment Aminoglutethimide , by Region USD Million (2021-2026)
  • Table 109. Cushing’s Disease Treatment Metyrapone , by Region USD Million (2021-2026)
  • Table 110. Cushing’s Disease Treatment Mifepristone , by Region USD Million (2021-2026)
  • Table 111. Cushing’s Disease Treatment Etomidate , by Region USD Million (2021-2026)
  • Table 112. Cushing’s Disease Treatment Pasireotide , by Region USD Million (2021-2026)
  • Table 113. Cushing’s Disease Treatment: by Cushing’s Syndrome(USD Million)
  • Table 114. Cushing’s Disease Treatment Iatrogenic Cushing’s Syndrome , by Region USD Million (2021-2026)
  • Table 115. Cushing’s Disease Treatment Endogenous Cushing’s Syndrome , by Region USD Million (2021-2026)
  • Table 116. Cushing’s Disease Treatment: by End User(USD Million)
  • Table 117. Cushing’s Disease Treatment Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 118. Cushing’s Disease Treatment Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 119. Cushing’s Disease Treatment Drug Stores , by Region USD Million (2021-2026)
  • Table 120. Cushing’s Disease Treatment Clinics , by Region USD Million (2021-2026)
  • Table 121. Cushing’s Disease Treatment E-Commerce/Online Pharmacies , by Region USD Million (2021-2026)
  • Table 122. South America Cushing’s Disease Treatment, by Country USD Million (2021-2026)
  • Table 123. South America Cushing’s Disease Treatment, by Drug USD Million (2021-2026)
  • Table 124. South America Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2021-2026)
  • Table 125. South America Cushing’s Disease Treatment, by End User USD Million (2021-2026)
  • Table 126. Brazil Cushing’s Disease Treatment, by Drug USD Million (2021-2026)
  • Table 127. Brazil Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2021-2026)
  • Table 128. Brazil Cushing’s Disease Treatment, by End User USD Million (2021-2026)
  • Table 129. Argentina Cushing’s Disease Treatment, by Drug USD Million (2021-2026)
  • Table 130. Argentina Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2021-2026)
  • Table 131. Argentina Cushing’s Disease Treatment, by End User USD Million (2021-2026)
  • Table 132. Rest of South America Cushing’s Disease Treatment, by Drug USD Million (2021-2026)
  • Table 133. Rest of South America Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2021-2026)
  • Table 134. Rest of South America Cushing’s Disease Treatment, by End User USD Million (2021-2026)
  • Table 135. Asia Pacific Cushing’s Disease Treatment, by Country USD Million (2021-2026)
  • Table 136. Asia Pacific Cushing’s Disease Treatment, by Drug USD Million (2021-2026)
  • Table 137. Asia Pacific Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2021-2026)
  • Table 138. Asia Pacific Cushing’s Disease Treatment, by End User USD Million (2021-2026)
  • Table 139. China Cushing’s Disease Treatment, by Drug USD Million (2021-2026)
  • Table 140. China Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2021-2026)
  • Table 141. China Cushing’s Disease Treatment, by End User USD Million (2021-2026)
  • Table 142. Japan Cushing’s Disease Treatment, by Drug USD Million (2021-2026)
  • Table 143. Japan Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2021-2026)
  • Table 144. Japan Cushing’s Disease Treatment, by End User USD Million (2021-2026)
  • Table 145. India Cushing’s Disease Treatment, by Drug USD Million (2021-2026)
  • Table 146. India Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2021-2026)
  • Table 147. India Cushing’s Disease Treatment, by End User USD Million (2021-2026)
  • Table 148. South Korea Cushing’s Disease Treatment, by Drug USD Million (2021-2026)
  • Table 149. South Korea Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2021-2026)
  • Table 150. South Korea Cushing’s Disease Treatment, by End User USD Million (2021-2026)
  • Table 151. Taiwan Cushing’s Disease Treatment, by Drug USD Million (2021-2026)
  • Table 152. Taiwan Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2021-2026)
  • Table 153. Taiwan Cushing’s Disease Treatment, by End User USD Million (2021-2026)
  • Table 154. Australia Cushing’s Disease Treatment, by Drug USD Million (2021-2026)
  • Table 155. Australia Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2021-2026)
  • Table 156. Australia Cushing’s Disease Treatment, by End User USD Million (2021-2026)
  • Table 157. Rest of Asia-Pacific Cushing’s Disease Treatment, by Drug USD Million (2021-2026)
  • Table 158. Rest of Asia-Pacific Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2021-2026)
  • Table 159. Rest of Asia-Pacific Cushing’s Disease Treatment, by End User USD Million (2021-2026)
  • Table 160. Europe Cushing’s Disease Treatment, by Country USD Million (2021-2026)
  • Table 161. Europe Cushing’s Disease Treatment, by Drug USD Million (2021-2026)
  • Table 162. Europe Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2021-2026)
  • Table 163. Europe Cushing’s Disease Treatment, by End User USD Million (2021-2026)
  • Table 164. Germany Cushing’s Disease Treatment, by Drug USD Million (2021-2026)
  • Table 165. Germany Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2021-2026)
  • Table 166. Germany Cushing’s Disease Treatment, by End User USD Million (2021-2026)
  • Table 167. France Cushing’s Disease Treatment, by Drug USD Million (2021-2026)
  • Table 168. France Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2021-2026)
  • Table 169. France Cushing’s Disease Treatment, by End User USD Million (2021-2026)
  • Table 170. Italy Cushing’s Disease Treatment, by Drug USD Million (2021-2026)
  • Table 171. Italy Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2021-2026)
  • Table 172. Italy Cushing’s Disease Treatment, by End User USD Million (2021-2026)
  • Table 173. United Kingdom Cushing’s Disease Treatment, by Drug USD Million (2021-2026)
  • Table 174. United Kingdom Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2021-2026)
  • Table 175. United Kingdom Cushing’s Disease Treatment, by End User USD Million (2021-2026)
  • Table 176. Netherlands Cushing’s Disease Treatment, by Drug USD Million (2021-2026)
  • Table 177. Netherlands Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2021-2026)
  • Table 178. Netherlands Cushing’s Disease Treatment, by End User USD Million (2021-2026)
  • Table 179. Rest of Europe Cushing’s Disease Treatment, by Drug USD Million (2021-2026)
  • Table 180. Rest of Europe Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2021-2026)
  • Table 181. Rest of Europe Cushing’s Disease Treatment, by End User USD Million (2021-2026)
  • Table 182. MEA Cushing’s Disease Treatment, by Country USD Million (2021-2026)
  • Table 183. MEA Cushing’s Disease Treatment, by Drug USD Million (2021-2026)
  • Table 184. MEA Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2021-2026)
  • Table 185. MEA Cushing’s Disease Treatment, by End User USD Million (2021-2026)
  • Table 186. Middle East Cushing’s Disease Treatment, by Drug USD Million (2021-2026)
  • Table 187. Middle East Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2021-2026)
  • Table 188. Middle East Cushing’s Disease Treatment, by End User USD Million (2021-2026)
  • Table 189. Africa Cushing’s Disease Treatment, by Drug USD Million (2021-2026)
  • Table 190. Africa Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2021-2026)
  • Table 191. Africa Cushing’s Disease Treatment, by End User USD Million (2021-2026)
  • Table 192. North America Cushing’s Disease Treatment, by Country USD Million (2021-2026)
  • Table 193. North America Cushing’s Disease Treatment, by Drug USD Million (2021-2026)
  • Table 194. North America Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2021-2026)
  • Table 195. North America Cushing’s Disease Treatment, by End User USD Million (2021-2026)
  • Table 196. United States Cushing’s Disease Treatment, by Drug USD Million (2021-2026)
  • Table 197. United States Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2021-2026)
  • Table 198. United States Cushing’s Disease Treatment, by End User USD Million (2021-2026)
  • Table 199. Canada Cushing’s Disease Treatment, by Drug USD Million (2021-2026)
  • Table 200. Canada Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2021-2026)
  • Table 201. Canada Cushing’s Disease Treatment, by End User USD Million (2021-2026)
  • Table 202. Mexico Cushing’s Disease Treatment, by Drug USD Million (2021-2026)
  • Table 203. Mexico Cushing’s Disease Treatment, by Cushing’s Syndrome USD Million (2021-2026)
  • Table 204. Mexico Cushing’s Disease Treatment, by End User USD Million (2021-2026)
  • Table 205. Research Programs/Design for This Report
  • Table 206. Key Data Information from Secondary Sources
  • Table 207. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cushing’s Disease Treatment: by Drug USD Million (2015-2020)
  • Figure 5. Global Cushing’s Disease Treatment: by Cushing’s Syndrome USD Million (2015-2020)
  • Figure 6. Global Cushing’s Disease Treatment: by End User USD Million (2015-2020)
  • Figure 7. South America Cushing’s Disease Treatment Share (%), by Country
  • Figure 8. Asia Pacific Cushing’s Disease Treatment Share (%), by Country
  • Figure 9. Europe Cushing’s Disease Treatment Share (%), by Country
  • Figure 10. MEA Cushing’s Disease Treatment Share (%), by Country
  • Figure 11. North America Cushing’s Disease Treatment Share (%), by Country
  • Figure 12. Global Cushing’s Disease Treatment share by Players 2020 (%)
  • Figure 13. BCG Matrix for key Companies
  • Figure 14. Corcept Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 15. Corcept Therapeutics (United States) Revenue: by Geography 2020
  • Figure 16. HRA Pharma (France) Revenue, Net Income and Gross profit
  • Figure 17. HRA Pharma (France) Revenue: by Geography 2020
  • Figure 18. Strongbridge Biopharma plc (United States) Revenue, Net Income and Gross profit
  • Figure 19. Strongbridge Biopharma plc (United States) Revenue: by Geography 2020
  • Figure 20. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 22. Global Cushing’s Disease Treatment: by Drug USD Million (2021-2026)
  • Figure 23. Global Cushing’s Disease Treatment: by Cushing’s Syndrome USD Million (2021-2026)
  • Figure 24. Global Cushing’s Disease Treatment: by End User USD Million (2021-2026)
  • Figure 25. South America Cushing’s Disease Treatment Share (%), by Country
  • Figure 26. Asia Pacific Cushing’s Disease Treatment Share (%), by Country
  • Figure 27. Europe Cushing’s Disease Treatment Share (%), by Country
  • Figure 28. MEA Cushing’s Disease Treatment Share (%), by Country
  • Figure 29. North America Cushing’s Disease Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Corcept Therapeutics (United States)
  • HRA Pharma (France)
  • Strongbridge Biopharma plc (United States)
  • Novartis AG (Switzerland)
Select User Access Type

Key Highlights of Report


May 2021 232 Pages 91 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Cushing’s Disease Treatment Market Quantitative research analysis
Global Cushing’s Disease Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Cushing’s Disease Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Follicular Lymphoma Drugs Comprehensive Study by Drug (Brand, Generic), Therapy (Mono, Combinational (Tazemetostat, Lenalidomide, CAR-T therapies Kymriah, Yescarta)), Treatment (Radiation, Chemothera...
$ 3650
Warts Comprehensive Study by Drug (Brand, Generic), Type (Common Warts, Flat Warts, Pigmented Warts, Plantar Warts), Treatment (Salicylic acid, Duct tape, Cryotherapy, Urgery, Laser treatment, Electr...
$ 3750
Controlled Substance Comprehensive Study by Type (Opioids, Stimulants, Depressants, Cannabinoids), Treatment (Pain management, Sleep disorders, Depression and anxiety, Seizure, Attention Deficit Hype...
$ 3650
Tetrabenazine Comprehensive Study by Application (Hospital Dispensaries, Retail Pharmacies, Online Third-Party Websites), Indication (Huntington's Disease, Tourette Syndrome and Tic Disorders, Tardiv...
$ 3650
Ankle Arthritis Treatment Comprehensive Study by Drug (Corticosteroids, Non-steroidal anti-inflammatory drugs, Steroids, Analgesics, Pain relievers, Anti-rheumatic drugs), Type (Ankle osteoarthritis,...
$ 3750
Homeopathic Veterinary Medicines Comprehensive Study by Application (Domestic Animals, Companion Animals), Distribution Channel (Retail Pharmacies, Veterinary Clinics, Online Pharmacies), Source of O...
$ 3350